MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Friday, November 21, 2008

PI-2301 for Multiple Sclerosis - designed to be taken weekly

Certain peptides and peptide copolymers composed are able to affect the activity of the CD4+ T-cells involved in the development and progression of multiple sclerosis.

Peptimmune’s most advanced drug, PI-2301, is a multiple sclerosis treatment designed to be taken weekly. It would compete with Teva Pharmaceutical Industries Ltd.’s daily treatment Copaxone, which generated $1.7 billion in sales last year. Peptimmune is counting on positive data from a study due in 2009 to show its drug is better than Copaxone.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone®, and it is expected to have superior efficacy and convenience profile compared to current immunomodulating agents for the treatment of multiple sclerosis.

Read more of Peptimmune by reading >> their website <<

Then, remain up-to-date with MS News, by registering to receive
"Stu's Views and MS Related News", a weekly distributed e-Newsletter

No comments: